'Sanofi Taps Adviser For OTC Spinoff As Buyout Firms Circle; French Pharma Firm Working With Rothschild On Separate Listing; Private Equity Funds Eye Sanofi Arm Valued At Over $20B' - Bloomberg News
Portfolio Pulse from Benzinga Newsdesk
Sanofi is consulting with Rothschild & Co. to prepare for a potential spinoff of its over $20 billion-valued consumer health division, with private equity firms showing interest in the unit.
November 15, 2023 | 5:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sanofi is considering a spinoff of its consumer health division, potentially valued over $20 billion, which could attract significant investor interest and impact stock performance.
The news of Sanofi working with Rothschild to potentially spin off its consumer health division suggests a strategic move that could unlock shareholder value and attract interest from private equity firms. This could lead to a positive market reaction in the short term as investors anticipate the realization of value from the spinoff. The valuation of over $20 billion indicates a significant portion of Sanofi's business, which underscores the importance of this news for investors.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100